BTAI — BioXcel Therapeutics Balance Sheet
0.000.00%
Last trade - 00:00
- $85.37m
- -$4.59m
- $1.38m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | |
Standards: | USG | USG | USG | USG | — |
Status: | Final | Final | Final | Final | fx Preliminary |
Cash and Equivalents | |||||
Cash and Short Term Investments | 32.4 | 213 | 233 | 194 | — |
Net Total Accounts Receivable | |||||
Net Total Receivables | — | — | — | 0.248 | — |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 34.1 | 217 | 237 | 203 | — |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 2.23 | 2.78 | 2.54 | 2.06 | — |
Other Long Term Assets | |||||
Total Assets | 36.4 | 220 | 239 | 206 | — |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 8.47 | 11.8 | 16.7 | 32.9 | — |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 9.5 | 13.2 | 17.8 | 129 | — |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Total Equity | 26.9 | 207 | 222 | 76.8 | — |
Total Liabilities & Shareholders' Equity | 36.4 | 220 | 239 | 206 | — |
Total Common Shares Outstanding |